The effects of acetaminophen on the rewarding properties of hydrocodone in rats

对乙酰氨基酚对大鼠氢可酮奖赏特性的影响

基本信息

  • 批准号:
    7781129
  • 负责人:
  • 金额:
    $ 3.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The illicit abuse of prescription opioid analgesics has been on the rise in recent years. This illicit use has been associated to the rewarding/reinforcing properties of opioid agonists. However, many prescription opioid analgesics contain a combination of two compounds: an opioid agonist, such as hydrocodone, plus a non-narcotic analgesic, such as acetaminophen. Although the combination analgesic formulations have been effective in treating pain, it is yet unknown whether the combined formulations possess greater rewarding properties, as compared to the opioid agonist alone, which may lead to greater use and abuse. Acetaminophen is not known to contain rewarding effects; however, it could possibly potentiate the rewarding properties of opioid agonists, such as hydrocodone, when combined. Interestingly, recent findings suggest that the analgesic actions of acetaminophen occur through its active metabolites. In particular, acetaminophen is metabolized into AM404, known to be a transporter blocker of the endocannabinoid anandamide, as well as an agonist for transient receptor potential vanilloid type 1 (TRPV1) receptors. We, therefore, hypothesize that acetaminophen will enhance/potentiate the rewarding properties of hydrocodone in rats through this novel mechanism. Therefore, in a series of experiments, we propose to address whether acetaminophen is able to enhance the rewarding properties of hydrocodone using the conditioned place preference paradigm. We will also address whether the enhancing effects of acetaminophen on hydrocodone reward can be blocked by prevention of AM404 formation. Lastly, we will address if the actions of acetaminophen on hydrocodone reward can be blocked by antagonism of CB1 or TRPV1 receptors. Funds provided by this funding opportunity can facilitate and supplement our current start-up research funds that have been provided by the College of Pharmacy at Western University of Health Sciences. PUBLIC HEALTH RELEVANCE: There has been a significant increase in the non-medical (illicit) use of prescription opioid analgesics in the United State over the past decade. Our project is set to determine whether prescription opioid analgesics that contain a combination of the two compounds, hydrocodone and acetaminophen (commercially known as Vicodin(R)), possess a greater rewarding effect than the individual drugs. The findings from this project will shed light on the abuse liability of drugs, such as Vicodin, and will advance our understanding as to why there has been an increase in the illicit use and abuse of prescription opioid analgesic drugs.
描述(申请人提供):近年来,处方阿片类镇痛剂的非法滥用呈上升趋势。这种非法使用与阿片类激动剂的奖励/强化特性有关。然而,许多处方阿片类止痛药含有两种化合物的组合:阿片类激动剂,如氢可酮,加上非麻醉性止痛剂,如对乙酰氨基酚。尽管联合止痛剂在治疗疼痛方面有效,但与阿片类激动剂单独使用相比,联合止痛剂是否具有更大的回报特性尚不清楚,这可能会导致更多的使用和滥用。目前还不知道对乙酰氨基酚具有奖赏作用;然而,当联合使用时,它可能会增强阿片激动剂(如氢可酮)的奖赏特性。有趣的是,最近的研究结果表明,对乙酰氨基酚的镇痛作用是通过其活性代谢物实现的。特别是,对乙酰氨基酚被代谢成AM404,已知是内源性大麻素ANAND酰胺的转运体阻滞剂,也是瞬时受体潜在香草素1型(TRPV1)受体的激动剂。因此,我们假设对乙酰氨基酚将通过这一新机制增强/增强氢可酮在大鼠中的奖赏特性。因此,在一系列实验中,我们建议使用条件性位置偏好范式来研究对乙酰氨基酚是否能够增强氢可酮的奖赏特性。我们还将讨论是否可以通过阻止AM404的形成来阻断对乙酰氨基酚对氢可酮奖赏的增强作用。最后,我们将讨论对乙酰氨基酚对氢可酮奖赏的作用是否可以通过CB1或TRPV1受体的拮抗来阻断。这一资助机会提供的资金可以促进和补充我们目前由西部健康科学大学药学院提供的创业研究资金。 与公共卫生有关:在过去十年中,美国非医疗(非法)使用处方阿片类镇痛剂的情况大幅增加。我们的项目旨在确定含有氢可酮和对乙酰氨基酚(商业上称为Vicodin(R))这两种化合物组合的处方阿片类止痛药是否比单独的药物具有更大的回报作用。该项目的调查结果将有助于阐明维柯丁等药物的滥用责任,并将有助于我们理解为什么处方阿片类止痛药的非法使用和滥用有所增加。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arbi Nazarian其他文献

Arbi Nazarian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arbi Nazarian', 18)}}的其他基金

Pain-induced impulsivity in rats and its mechanisms
疼痛诱发大鼠冲动及其机制
  • 批准号:
    10359932
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
Insulin mechanisms of diabetes-evoked enhancement of nicotine reward
糖尿病引起尼古丁奖赏增强的胰岛素机制
  • 批准号:
    9238041
  • 财政年份:
    2016
  • 资助金额:
    $ 3.75万
  • 项目类别:
The effects of acetaminophen on the rewarding properties of hydrocodone in rats
对乙酰氨基酚对大鼠氢可酮奖赏特性的影响
  • 批准号:
    7921006
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了